https://orcid.org/0000-0001-8257-1816
References
- Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:1590.
- Strober BE, van der Walt JM, Armstrong AW, et al. Clinical goals and barriers to effective psoriasis care. Dermatol Ther. 2019;9(1):5–18.
- Kolli SS, Amin SD, Pona A, et al. Psychosocial impact of psoriasis: a review for dermatology residents. Cutis. 2018;102(5S):21–25.
- Goff KL, Karimkhani C, Weinstock MA, et al. The global burden of psoriatic skin disease. Br J Dermatol. 2015;172(6):1665–1668.
- Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10.
- Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):509–519.
- Yiu Z, Mason K, Reynolds N, et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2020;183(2):294–302.
- Gutknecht M, Krensel M, Augustin M. Health economic analyses of psoriasis management: a systematic literature search. Arch Dermatol Res. 2016;308(9):601–616.
- Mauskopf J, Samuel M, McBride D, et al. Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines. Pharmacoeconomics. 2014;32(4):395–409.
- Johansson E, Hartz S, Kiri S, et al. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK. J Med Econ. 2018;21(8):810–820.
- Klijn S, van den Reek J, van de Wetering G, et al. Biologic treatment sequences for plaque psoriasis: a cost–utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE. Br J Dermatol. 2018;178(5):1181–1189.
- Augustin M, Wirth D, Mahlich J, et al. Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany. J Dermatolog Treat. 2020;1–7.
- European Medicines Agency. Cimzia®: summary of product characteristics [Internet]; 2020 [cited 2020 Jul 2]. Available from: https://www.ema.europa.eu/en/documents/product-information/cimzia-epar-product-information_en.pdf
- European Medicines Agency. Cosentyx®: summary of product characteristics [Internet]; 2020 [cited 2020 Jul 2]. Available from: https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf
- European Medicines Agency. Hulio®: summary of product characteristics [Internet]; 2020 [cited 2020 Jul 2]. Available from: https://www.ema.europa.eu/en/documents/product-information/hulio-epar-product-information_en.pdf
- European Medicines Agency. Kyntheum®: summary of product characteristics [Internet]; 2019 [cited 2020 Jul 2]. Available from: https://www.ema.europa.eu/en/documents/product-information/kyntheum-epar-product-information_en.pdf
- European Medicines Agency. SkyriziTM: summary of product characteristics [Internet]; 2020 [cited 2020 Jul 2]. Available from: https://www.ema.europa.eu/en/documents/product-information/skyrizi-epar-product-information_en.pdf
- European Medicines Agency. Stelara®: summary of product characteristics [Internet]; 2020 [cited 2020 Jul 2]. Available from: https://www.ema.europa.eu/en/documents/product-information/stelara-epar-product-information_en.pdf
- European Medicines Agency. Taltz: summary of product characteristics [Internet]; 2020 [cited 2020 Jul 2]. Available from: https://www.ema.europa.eu/en/documents/product-information/taltz-epar-product-information_en.pdf
- European Medicines Agency. Tremfya®: summary of product characteristics [Internet]; 2020 [cited 2020 Jul 2]. Available from: https://www.ema.europa.eu/en/documents/product-information/tremfya-epar-product-information_en.pdf
- Yasmeen N, Sawyer L, Malottki K, et al. Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. J Dermatolog Treat. 2020.
- Egeberg A, Bryld L, Skov L. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019;81:193–178.
- Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40.
- Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43–53.